Acute Decompensated Heart Failure in a Young Patient Infected with COVID-19

Gil Hevroni¹, Diego Cepeda-Mora¹, Zachary Mostel¹, Luis Lugo¹ and Samy I McFarlane^1,

¹Department of Internal Medicine, SUNY-Downstate Health Science University, Brooklyn, New York, USA11203

Cite this paper

Gil Hevroni, Diego Cepeda-Mora, Zachary Mostel, Luis Lugo and Samy I McFarlane. Acute Decompensated Heart Failure in a Young Patient Infected with COVID-19. American Journal of Medical Case Reports. 2021; 9(3):163-166. doi: 10.12691/AJMCR-9-3-8

Abstract

While patients with severe COVID-19 infection often have cardiovascular comorbidities, there is a paucity of literature outlining the potential of this novel coronavirus to trigger acute decompensated heart failure. To date, there is limited understanding of the pathophysiology of heart failure in COVID-19; some suggest decompensation is a result of an incident episode of myocarditis as seen with other respiratory viruses. Here we present a case of a 25 year old man with no known cardiovascular disease, who presented with acute decompensated heart failure found to have an ejection fraction of ten percent in the setting of COVID-19 infection and subsequently had multiple admissions for heart failure decompensation. An extensive work-up was performed and ruled out cardiovascular and rheumatological causes of heart failure, making COVID-19 infection a plausible etiologic factor for heart failure.

Keywords

heart failure, COVID-19, SARS-CoV-2, myocarditis, cardiovascular disease

Copyright

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References

[1]	Nishiga M, Wang DW, Han Y, Lewis DB, Wu JC. COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives. Nat Rev Cardiol. 2020 Sep; 17(9): 543-558.
[2]	Ranard, Lauren S., et al. “Approach to Acute Cardiovascular Complications in COVID-19 Infection.” Circulation: Heart Failure, vol. 13, no. 7, 2020.
[3]	Badawi A, Ryoo SG. Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis.Int J Infect Dis. 2016; 49: 129-133.
[4]	Zheng YY, Ma YT, Zhang JY, Xie X. Reply to: ‘Interaction between RAAS inhibitors and ACE2 in the context of COVID-19.’Nat Rev Cardiol. 2020; 17: 313-314.
[5]	Goyal P, Choi JJ, Pinheiro LC, Schenck EJ, Chen R, Jabri A, Satlin MJ, Campion TR, Nahid M, Ringel JB. Clinical characteristics of Covid-19 in New York City.N Engl J Med. 2020; 382:2372-2374.
[6]	Petrilli CM, Jones SA, Yang J, Rajagopalan H, O’Donnell LF, Chernyak Y, Tobin K, Cerfolio RJ, Francois F, Horwitz LI. Factors associated with hospitalization and critical illness among 4,103 patients with COVID-19 disease in New York City.medRxiv.
[7]	Arentz M, Yim E, Klaff L, Lokhandwala S, Riedo FX, Chong M, Lee M. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State.JAMA. 2020; 323: 1612-1614.
[8]	Ranard LS, Fried JA, Abdalla M, Anstey DE, Givens RC, Kumaraiah D, Kodali SK, Takeda K, Karmpaliotis D, Rabbani LE, Sayer G, Kirtane AJ, Leon MB, Schwartz A, Uriel N, Masoumi A. Approach to Acute Cardiovascular Complications in COVID-19 Infection. Circ Heart Fail. 2020 Jul; 13(7): e007220.
[9]	Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, et al.. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.Lancet. 2020; 295: 1054-1062.
[10]	Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395(10223): 497-506.
[11]	Zhyvotovska A, Yusupov D, Foronjy R, Nakeshbandi M, McFarlane SI, Salifu M. Insights into Potential Mechanisms of Injury and Treatment Targets in COVID-19, SARS-Cov-2 Infection. Int J Clin Res Trials. 2020; 5(1): 147.
[12]	Rizzo P, Vieceli Dalla Sega F, Fortini F, Marracino L, Rapezzi C, Ferrari R. COVID-19 in the heart and the lungs: could we "Notch" the inflammatory storm? Basic Res Cardiol. 2020 Apr 9; 115(3): 31.
[13]	Riski H, Hovi T, Frick MH. Carditis associated with coronavirus infection. Lancet 1980; 2: 100-101.
[14]	Alhogbani T. Acute myocarditis associated with novel Middle East respiratory syndrome coronavirus. Ann Saudi Med 2016; 36: 78-80.
[15]	Gheblawi M, Wang K, Viveiros A, Nguyen Q, Zhong J-C, Turner AJ, et al. Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2. Circ Res. 2020 May 8; 126(10): 1456-74.
[16]	Biesbroek PS, Beek AM, Germans T, Niessen HW, van Rossum AC. Diagnosis of myocarditis: Current state and future perspectives. Int J Cardiol. 2015 Jul 15; 191: 211-9.
[17]	Alida L. P. Caforio, Sabine Pankuweit, et al, Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases, European Heart Journal, Volume 34, Issue 33, 1 September 2013, Pages 2636-2648,
[18]	Lindner D, Fitzek A, Bräuninger H, et al. Association of cardiac infection with SARS-CoV-2 in confirmed COVID-19 autopsy cases. JAMA Cardiol. Published online July 27, 2020.